327
Views
14
CrossRef citations to date
0
Altmetric
Drug Evaluations

Degarelix for prostate cancer

, MD PhD, &
Pages 851-860 | Published online: 20 May 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Bin Yang, Ana Gomes Dos Santos, Sanyogitta Puri, Annette Bak & Liping Zhou. (2022) The industrial design, translation, and development strategies for long-acting peptide delivery. Expert Opinion on Drug Delivery 19:10, pages 1233-1245.
Read now
Kamal Kant Sahu, Nishita Tripathi, Neeraj Agarwal & Umang Swami. (2022) Relugolix in the management of prostate cancer. Expert Review of Anticancer Therapy 22:9, pages 891-902.
Read now

Articles from other publishers (12)

Motohiro Tezuka, Yasuaki Tamai, Yu Kuramochi, Kaoru Kobayashi, Nobuhiko Fushimi & Sumiyoshi Kiguchi. (2022) Pharmacological characterization of linzagolix, a novel, orally active, non‐peptide antagonist of gonadotropin‐releasing hormone receptors. Clinical and Experimental Pharmacology and Physiology 49:10, pages 1082-1093.
Crossref
Michelle Anne Kutzler. (2018) Estrus Suppression in Dogs. Veterinary Clinics of North America: Small Animal Practice 48:4, pages 595-603.
Crossref
Jathin Bandari, Robert M. TurnerIIII, Bruce L. Jacobs, David Canes, Ali Moinzadeh & Benjamin J. Davies. (2017) The Relationship of Industry Payments to Prescribing Behavior: A Study of Degarelix and Denosumab. Urology Practice 4:1, pages 14-20.
Crossref
Seon-Mi Kim, Minhee Lee, So Young Lee, Euisun Park, Soo-Min Lee, Eun Jeong Kim, Min Young Han, Taekyung Yoo, Jihyae Ann, Suyoung Yoon, Jiyoun Lee & Jeewoo Lee. (2016) Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist. Journal of Medicinal Chemistry 59:19, pages 9150-9172.
Crossref
Seon Mi Kim, Taekyung Yoo, So Young Lee, Eun Jeong Kim, Soo Min Lee, Min Hee Lee, Min Young Han, Seung-Hyun Jung, Jung-Hye Choi, Keun Ho Ryu & Hun-Taek Kim. (2015) Effect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic?pituitary?gonadal axis. Life Sciences 139, pages 166-174.
Crossref
Daisuke Nakata, Tsuneo Masaki, Akira Tanaka, Mie Yoshimatsu, Yumiko Akinaga, Mari Asada, Reiko Sasada, Michiyasu Takeyama, Kazuhiro Miwa, Tatsuya Watanabe & Masami Kusaka. (2014) Suppression of the hypothalamic–pituitary–gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock-in mice. European Journal of Pharmacology 723, pages 167-174.
Crossref
Xiaoli Zhang, Yajuan Song, Yuanyuan Wu, Yanmin Dong, Li Lai, Jing Zhang, Binbin Lu, Fujun Dai, Lijun He, Mingyao Liu & Zhengfang Yi. (2011) Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2‐mediated JAK/STAT3 signaling in endothelial cell . International Journal of Cancer 129:10, pages 2502-2511.
Crossref
Xue Jun Wang, Kai Gu, Jin Shu Xu, Ming Hui Li, Rong Yue Cao, Jie Wu, Tai Ming Li & Jing Jing Liu. (2010) Immunization with a recombinant GnRH vaccine fused to heat shock protein 65 inhibits mammary tumor growth in vivo. Cancer Immunology, Immunotherapy 59:12, pages 1859-1866.
Crossref
. (2010) Current World Literature. Current Opinion in Supportive & Palliative Care 4:3, pages 207-227.
Crossref
Gloria Ruiz-Gómez, Joel D. A. Tyndall, Bernhard Pfeiffer, Giovanni Abbenante & David P. Fairlie. (2010) Update 1 of: Over One Hundred Peptide-Activated G Protein-Coupled Receptors Recognize Ligands with Turn Structure. Chemical Reviews 110:4, pages PR1-PR41.
Crossref
Michael Marberger, Amir V Kaisary, Neal D. Shore, Gary S. Karlin, Claudio Savulsky, Ricard Mis, Chiara Leuratti & Josep R. Germa. (2010) Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: A phase III, open-label, international multicenter study. Clinical Therapeutics 32:4, pages 744-757.
Crossref
Ilpo Huhtaniemi. 2010. Neuroendocrinology: The Normal Neuroendocrine System. Neuroendocrinology: The Normal Neuroendocrine System 273 288 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.